Unlock cells. Deliver innovation. PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle. Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids. As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers. Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise …

78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing innovative therapies to patients Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pan Cancer T is a biotech company developing T cell receptor (TCR) T-cell therapy for solid tumours Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leman Biotech, a spin-off company of EPFL, aims at developing and commercializing new metabolic cancer immunotherapies Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring …

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Discovering the relationships at the heart of biology to cure disease. We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select …

135 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. At Inventiva, we are united in developing differentiated treatments for MASH and making a meaningful difference in the lives of those affected. Recognizing that MASH is not just a liver disease but also a cardiometabolic condition, we have purposefully designed a potential oral therapy — currently in clinical development — intended to restore metabolic balance at the source and directly target inflammation and fibrosis. Our goal is to bring relief to patients across the MASH patient population, addressing a critical unmet need in a progressive and life-threatening …

95 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and …

78 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Empower the body, cure the disease Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination of in-silico and wet-lab pipelines to uncover new tumour-specific targets (called E-antigens) derived from the unexploited dark genome, and to develop multiple therapeutic modalities (i.e. cell therapy, TCE, ADC, vaccine) targeting these E-antigens. Mnemo is currently pursuing several discovery campaigns for E-antigens, with a plan to develop its proprietary tumour-specific …

61 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology

Translational Pharmacology and Preclinical Services for Oncology, Inflammation, and Radiopharmaceutical Research Oncodesign Services supports biopharma and biotechnology teams navigating critical preclinical decisions as programs progress toward the clinic. At this stage, generating data alone is not enough; what matters is whether the evidence genuinely supports the next step forward. We are a preclinical contract research organization specializing in advanced development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases. Our work is focused on the translational phase of drug development, where scientific rigor, careful study design, and clear interpretation are essential to support confident progression toward IND and …

83 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

LYMPHOGENiX is a leading company for lymphatic vessel regeneration research based in the UK and Japan operating globally LYMPHOGENiX is a UK-based biotechnology company focused on developing first-in-class therapeutics for infertility, leveraging a novel and underexplored biological system: the lymphatic vasculature. Infertility remains a major and growing global health challenge, affecting millions of individuals and couples worldwide. Despite advances in assisted reproductive technologies, implantation failure and poor endometrial receptivity continue to limit success rates. LYMPHOGENiX was founded to address this unmet need by targeting a fundamental but overlooked component of reproductive biology. Our core scientific insight is that lymphatic vessels …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

INDIVIDUALIZED NK CELL THERAPIES XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody, isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients. At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Development of CAR-T cell based cancer therapies T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genetic medicines for age-related diseases Oisín Biotechnologies is developing a new class of genetic medicines that target the biology of aging. We don't make pills or supplements; we build powerful, redosable genetic therapies and start with indications regulators already understand, so we can attack the mechanisms of age-related decline on a path that leads to approval. Our therapies are built on the Fusogenix Proteo-Lipid Vehicle (PLV), a non-viral delivery technology that fuses directly with target-cell membranes to deliver both DNA and RNA payloads. Delivery has been the Achilles' heel of genetic medicine. Viral approaches can't be safely redosed, carry limited …

89 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Levearging the therapeutic potential of mitochondria cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation. Therapeutic Mitochondria Transfer, Mitochondria, Ischemia-Reperfusion Injury, and Solid Organ Transplantation

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives. Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit. Kura developed and is commercializing KOMZIFTITM (ziftomenib), the …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused …

110 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

seRNA – enter the next level of mRNA technology It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets indications of highest medical need. Many devastating diseases cannot be effectively treated. Even if therapies exist, often they don’t specifically target the diseased area, leading to a high risk of severe side effects. To overcome this inherent problem, we have developed seRNA as a new RNA-based therapy approach.

59 similar entities Type: Startup Activities: deeptech biotech

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Powering New Possibles in Cell Therapy Manufacturing Cell therapy has transformed cancer treatment, yet the hurdles of manufacturing patient-derived cell therapies remain a formidable challenge for the industry. Quality and scalability problems lead to high therapeutic costs and limit access to those life-saving treatments. By harnessing the power of cutting-edge semiconductor technologies, including silicon photonics seamlessly integrated into microfluidic cartridges, Sarcura is orchestrating a transformative shift. Central to Sarcura's mission is the creation of fully automated manufacturing systems endowed with real-time process and product control. This pioneering platform promises to usher in a new era of cost-effective and secure cell …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Translating ET biology into novel therapies for immune-mediated inflammatory diseases Citryll has translated a deep understanding of the extracellular trap (ET) pathway to therapeutically address its central role in a broad range of immune-mediated inflammatory diseases (IMIDs). With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control ETs and ETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of IMIDs. Immunology, Therapeutics development, Neutrophil Extracellular Traps, Inflammatory diseases, …

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and …

72 similar entities Tags: FrenchTech120 Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting Beta Cell recovery in Diabetes DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France). Biotechnology and Diabetes

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We want every patient to become a Cancer Survivor. Cure 51 is a TechBio aiming at creating the first ever worldwide database of Cancer Survivors. The company was co-created with leading oncology centres and has already identified more than 1500 survivors in 42 countries across all continents. The company has developed its own data collection and discovery platform as well as a dedicated Central Lab to proceed to a multiomic sequencing of the survivors’ samples. Through this approach, Cure51 will identify robust therapeutic targets, validated by its scientific community, in order to develop novel drugs to cure Cancer. The focus …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME) TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the next generation bacterial cancer therapy Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Inventing a new class of medicines using Targeted Protein Degradation Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer immunotherapy by targeting the unconventional Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Through our proprietary EnTiCE platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery and development of novel therapeutics targeting transcription factors in cancer and other diseases QUANTRO Therapeutics (“QUANTRO”) is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology (“IMBA”) and the Research Institute …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dark Genome-Derived Therapeutics Targeting Cellular Senescence in Cancer & Metabolic Disease Advancing immunotherapies targeting “dark genome” antigens, specifically HERV-K. Aberrant activation and expression of HERV-K in chronic inflammation, metabolic stress, cancer, and aging — drive immune evasion, senescence, and metabolic dysfunction and disease. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of inflammation, type-2 diabetes disease, oncology, and longevity. Oncology, Aging, Dark Genome, ALS, Diabetes, Longevity, and Senescense

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cure with genes Healthy cells for healthy people Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, …

77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-PrimeTM, and novel drug candidates based on the RUBYTM bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator ́s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more …

73 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Biologics Through Chemistry Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crescendo Biologics - The T cell Enhancing Company Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases. Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. Our autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 …

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailored to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Specificity is everything TauC3 Biologics is developing a disease-modifying treatment for tauopathies, including frontotemporal dementia due to tau pathology (FTD-tau) and progressive supranuclear palsy (PSP). Tauopathies are devastating and ultimately fatal neurodegenerative diseases typically manifesting as progressive dementia or movement impairment. Brain examination reveals abnormal deposits of tau protein that are believed to be preceded by toxic, soluble forms that lead to neuronal death. Currently in preclinical development, the company’s therapeutic candidate, TBL-100, is a humanized monoclonal antibody that uniquely targets a truncated form of tau known as tauC3 that appears to be highly elevated in these conditions. TauC3, is …

59 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The ISTCT unit “Imaging and Therapeutic Strategies for Cancers and Brain Tissues”, UMR6030 is a joint research unit of the CNRS and the University of Caen-Normandy (UNICAEN) hosted at the GIP CYCERON in Caen. ISTCT's research activities aim to better understand the pathophysiology of hypoxic tumors (brain-lung) and identify new therapeutic strategies targeting the tumor and its microenvironment but also to protect the surrounding healthy tissue from anti-cancer treatments such as radiotherapy. For example, in addition to molecular and/or cellular strategies targeting hypoxia, ISTCT is studying the benefit of hadrons (carbon and proton ions) in combination with other therapies (chemotherapy, …

62 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing a next generation, immunomodulatory treatment, for mild to moderate atopic dermatitis. Pharmability originated from a pivotal scientific discovery made at the Karolinska Institutet, where Professor Anna-Lena Spetz uncovered the unique immunomodulatory potential of a single-stranded oligonucleotide, now known as TIR-01. Unlike conventional therapies that broadly suppress the immune system, TIR-01 demonstrated the ability to modulate immune responses with precision, laying the groundwork for a new class of treatments for autoimmune and inflammatory diseases. This novel mechanism of action opened the door to developing safer and more targeted therapies, an approach that has become central to TIRmed's mission. Since its …

62 similar entities Type: Startup Activities: deeptech biotech

AI-powered and patient-inspired. We accelerate the discovery and development of rare disease treatments. Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop treatments to give hope back to patients. Tratamientos que devuelven la esperanza a los pacientes. We are a biotechnology company that develops effective and safe therapeutic treatments for cancer with the purpose of restoring hope to patients who have no other option. We have been studying cancer and especially its relationship with inflammation for more than 7 years. Somos una empresa biotecnológica que desarrolla tratamientos terapéuticos eficaces y seguros contra el cáncer con el propósito de devolver la esperanza a pacientes que no tienen otra opción. Llevamos más de 7 años estudiando el cáncer y especialmente su relación …

96 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Novel Biotech dual-platform: therapeutic and drug-delivery MediSieve is a biotech developing a novel Magnetic Blood Filtration technology. Our nanoengineered magnetic particles enable the selective removal of specific substances - such as pathogens, antibodies, and inflammatory cytokines - from the bloodstream, much like dialysis, but with unmatched precision. Our platform's versatility allows for the selective removal of virtually any target, with our lead asset focused on neutralising antibody (NAb) removal to enhance AAV gene therapies for both initial dosing and redosing. Magnetic blood filtration and Blood-borne disease treatment

62 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Pushing the limits of conventional chemotherapy Doxanano is committed to pushing the limits of conventional chemotherapy for patients with solid tumors. Our goal is to significantly increase the selective delivery of chemotherapeutic agents into the tumor whilst dramatically limiting adverse effects on healthy organs. We specialize in harnessing the unique properties of our DXN polymersomes drug delivery platform in combination with the precision of radiotherapy.

77 similar entities Type: Startup Activities: deeptech Technologies: SaaS Synthetic Biology

Making FLASH radiation therapy accessible to all. THERYQ is an innovative medical device company specializing in the design, manufacture and commercialization of FLASH radiotherapy systems. THERYQ aims to expand the use of radiotherapy in oncology and unlock new treatments for patients with cancer. We want to improve patient care and have a positive impact on patients' lives, expectancies, and quality of life by providing efficient, precise, ultra-short radiation treatments. FLASH radiotherapy offers new possibilities and hope for cancer patients all over the world. radiotherapy, medical device, oncology, cancer, electron linac, and flash radiotherapy

62 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Solutions to deprogram cell death : A breakthrough innovation to treat and prevent severe pathologies We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided …

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors. immunologie and oncologie

116 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

265 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Neuroprotecting Patient's Future Saxol, newborn company develops innovative compounds able to fight and/or to prevent peripheral neuropathies, including Diabetes peripheral neuropathies, Immuno and Chemotherapy-Induced Peripheral Neuropathies (CIPN). Based on IAB research on Carbazole structure (Lafanechère Team) and with the support of Linksium, we plan to bring to patients, new neuroprotective drugs to answers current Unmet Medical needs CARBA1, our lead compound has neuroprotective activity through a mechanism of regulation and reactivation of energy production at the cellular level. We plan first to develop Carba1 for CIPN Unmet Medical Need and to enlarge after to Diabetes Peripheral Neuropathy DPN and other …

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A clinic-ready biotech developing human cell-derived secretome drugs to cure inflammation-related pathologies Med’Inn’Pharma (MIP) is a clinic-ready Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and of the French National Institute of Health (INSERM). MIP is a pioneer in developing a new class disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions. Our founders are world leaders in immunology and inflammation-resolution, and have developed a patent protected process to harness bioactive molecules from physiologically conditioned human cells into a stable biologic drug product. …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Immunotherapy Paths with Smart Peptides SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology. SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most. SPIMA Therapeutics is part of the nexus of Landmark Bioventures. Join us in shaping the future of medicine, where discovery meets dedication. Immunothery

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Basic and translational research on cancer, immunity, metabolism and chronic diseases, toward precision medicine. Basic and translational research on cancer, immunity, metabolism and chronic diseases, to make precision medicine a reality.

59 similar entities Type: SMB Activities: biotech deeptech

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovative therapies for peripheral nerve diseases Nervosave Therapeutics discovers and develops therapies that slow, stop and reverse a broad range of demyelinating peripheral nerve diseases. Our first aim is to develop best in class Gene Therapy for CMT1A patients and beyond for all demyelinating CMT diseases. We develop robust discovery programs targeting both CMT diseases and acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome.

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Swalife Biotech, we are at the forefront of developing next-generation therapies for cancer and chronic diseases. Our research is rooted in the discovery of five novel bioactive alkaloids from plants, aimed at synthesizing compounds that target key mechanisms in skin and breast cancer. We leverage cutting-edge technologies such as network pharmacology and AI to enhance our understanding and development of drug therapies. Our alkaloids have shown promising results in inhibiting the DNA Damage Response (DDR) pathway, crucial in preventing drug resistance and cancer cell survival. Our innovative approach not only targets cancer but also extends to managing chronic diseases, …

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Bio sourced materials

Targeting the Source. Transforming the Outcome. We develop miRNA-based therapies that address the root causes of neurological diseases. This goes far beyond the limitations of current treatment options, which only manage individual symptoms.

157 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Setting a new standard in precision oncology Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we …

77 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

We provide a safe and more effective solution for patients in need of platin-treatment. CHOSA Oncology is advancing precision medicine for platinum-based chemotherapy. Our patented Platin-DRP® technology analyses 205 tumour-specific genes to predict which patients will benefit from cisplatin or carboplatin treatment before therapy begins. By helping clinicians identify the right patients for platinum therapy, we aim to improve treatment outcomes, increase response rates, and reduce unnecessary toxicity. Supported by multiple clinical studies and Key Opinion Leaders, CHOSA is committed to setting a new standard in precision oncology and transforming how platinum chemotherapy is used.

59 similar entities Type: Startup Activities: healthtech deeptech

Reprogramming the solid Tumor Micro-Environment to unlock the full potential of cancer immunotherapy Lever Bio's goal is to develop novel immunomodulatory antibody-based therapeutics to overcome resistance to current immunotherapies, paving the way for next-generation immunotherapies and innovative combination treatments. Lever Bio's compounds target components of the solid tumor microenvironment to foster anti-cancer immune response enhancing recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors. Immuno-oncologia and Terapia Cellulare

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Idea Therapeutics is a Spanish biotech start-up focused on advanced therapy medicinal products (ATMPs), aiming to address diseases with limited therapeutic options. Our current research projects focus on regenerative medicine and immunology, with a long-term vision of expanding into other high-impact therapeutic areas such as oncology. At Idea Tx, we believe in the transformative power of science. Our mission is to investigate and develop disruptive ideas into new research lines in the field of ATMPs. We follow an open innovation model through strategic partnerships with leading public and private hospitals and research centers, integrating the entire value chain and driving …

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

MAAsiRNA develops a pioneering targeted therapy utilizing small interfering RNA (siRNA). A significant challenge in the field of nervous system pathologies lies in the absence of effective treatments. MAAsiRNA develops a pioneering targeted therapy utilizing small interfering RNA (siRNA). After over a decade of intensive interdisciplinary research, we have successfully developed a siRNA-based treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), the most prevalent form of hereditary peripheral neuropathy. CMT1A affects 1 in 5000 people, comprising a total of 1.5 million individuals worldwide. Our current objective is to advance towards a patient-ready therapy. Our innovative therapeutic approach has the potential to …

80 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Beyond Inhibition. Reprogramming Cancer Control. Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking new therapeutic pathways for metabolic health Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Theseus is developing best-in-class kinase inhibitors to shape the future of targeted oncology. Theseus Pharmaceuticals is passionately committed to outsmarting cancer resistance. Cancer is constantly mutating, allowing it to evade initially effective oncology treatments. Theseus believes we can predict how cancer will change, enabling new therapies to stay ahead of future mutations and overcome the demonstrated burden of treatment resistance. Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), we are developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology. PLEASE NOTE: All open positions for Theseus Pharmaceuticals will be …

55 similar entities Type: Startup Activities: it services Technologies: A.I. Synthetic Biology

Reconcile the time of Research with the one of Medecine APTEΞUS was created to provide clinicians and their patients suffering from orphan diseases, an innovative service of clinical biology that perfectly meets the emerging challenge of individualized medicine. APTEΞUS is engaged in patient-centric discovery of individualized treatments. Our technology allows the testing of thousands of molecules directly on primary cells sampled from patient with inborn error of metabolism. We can rapidly identify molecules that specifically correct the very molecular defect of the patient and give him a new opportunity to be cured.

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies for oncogene-driven cancers Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers. Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NuCana is a clinical-stage biopharmaceutical company developing an expansive portfolio of new medicines to treat cancer. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome …

83 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Changing the way cancer is fundamentally treated. ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic virotherapy, for the treatment of canine cancers. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Learn more at www.eliasanimalhealth.com. About ECI® The company's lead product, ELIAS Cancer Immunotherapy (ECI®), is the first-ever USDA-approved treatment for canine osteosarcoma, a deadly form of bone cancer in dogs. combines an autologous vaccine with cell therapy to target a patient’s …

69 similar entities Type: Startup Activities: pettech biotech healthtech deeptech Technologies: Synthetic Biology

Altevax is developing a disruptive immunotherapy technology against cancer Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment. Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies. Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development. The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development. Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pinpoint DNA medicine Cyllene Therapeutics is the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology. Cyllene Tx is currently executing a Phase 1/2 study in the US with its lead DNA medicine candidate, EG110A, in patients with neurogenic detrusor overactivity (neurogenic bladder)-related incontinence. This is the first human study with nrHSV vectors targeting sensory neuron-based diseases. EG110A is being developed to address multiple severe bladder diseases, including overactive bladder (OAB), and has the potential to be a major improvement over existing therapies, resulting in better care for patients and lower costs for healthcare systems. The company’s unique HERMES …

67 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Innovative science to improve the health of patients To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign …

116 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the immune system to fight cancer Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. For this purpose, Takis offers cutting-edge technologies and works with the idea that new cancer treatment must be based on in-depth knowledge of tumour biology and the concept of personalized cancer therapy. Together with some of its partners, Takis is involved in the identification of new biomarkers and in the development of molecular diagnostic …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers. Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Personalized Immunotherapy to Treat Cancer Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has …

99 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From library to life - breaking the barrier to solid tumours. Theolytics is an Oxford-based, clinical-stage biotechnology company developing differentiated intravenous oncolytic immunotherapies for solid tumours. From library to life - breaking the barrier to solid tumours. Solid tumours are difficult to treat with oncolytic viruses because most candidates cannot be delivered systemically, and because the tumour microenvironment (TME) suppresses the immune response needed for a durable effect. Our approach is built to address both problems. Our proprietary Adenovo platform applies natural selection from the world's largest adenovirus library to identify candidates with novel biology. Rather than engineering a single …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unmask Cancer, Elicit Immune Response Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors. Glyco Immuno Oncology

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the next generation of astatine-211 targeted alpha therapies & bifunctional antibodies. NAYA Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing oncology outcomes through the development of next-generation bifunctional antibodies. NAYA has developed a versatile plug and play bifunctional antibody construct that promotes avidity and a synapse effect, enhancing precision tumor killing. The company has two priority development franchises, Hepatocellular Carcinoma (HCC) and Multiple Myeloma, with an expanding portfolio of highly-differentiated assets that currently includes: NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of HCC with a unique mechanism of action targeting non-responders to the current immunotherapy …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics

Overcoming Tumor Drug Resistance Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes. Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis. Oncology

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Pioneering cancer immunotherapies targeting the immunosuppressive tumor microenvironment. Adaptam Therapeutics is pioneering next-generation cancer immunotherapies by disrupting the immunosuppressive myeloid tumor microenvironment (TME) through glyco-immune checkpoints. The TME in solid tumors is enriched in immunosuppressive myeloid cells, such as tumor-associated macrophages (TAMs), which drive resistance or a lack of response to existing treatments. This remains one of the toughest challenges in cancer immunotherapy. Our discoveries in cancer immunology, T cell and myeloid cell biology have revealed previously unexplored cancer dependencies, demonstrating that specific glycan interactions with immune cells are key drivers of myeloid-mediated immune suppression. Adaptam is advancing a pipeline …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology